FDA places clinical hold on Verve Therapeutics gene-editing treatment
Summary by Ground News
Verve Therapeutics says its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the FDA. The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment.Published 3 months ago
News Articles
More Filters
All
Left
Center
Right
Time & Location
Sources are mostly out of (0)